Personalis Announces Tempus Begins Commercialization Of NeXT Personal, An Ultra-Sensitive Liquid Biopsy Assay For Detecting Minimal Residual Disease And Cancer Recurrence
Personalis Announces Tempus Begins Commercialization Of NeXT Personal, An Ultra-Sensitive Liquid Biopsy Assay For Detecting Minimal Residual Disease And Cancer Recurrence
Personalis宣佈Tempus開始商業化neXT Personal,這是一種超靈敏的液體活檢檢測,用於檢測最低限度的殘留疾病和癌症復發
Personalis Announces Tempus Begins Commercialization Of NeXT Personal, An Ultra-Sensitive Liquid Biopsy Assay For Detecting Minimal Residual Disease And Cancer Recurrence
Personalis宣佈Tempus開始商業化neXT Personal,這是一種超靈敏的液體活檢檢測,用於檢測最低限度的殘留疾病和癌症復發
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。